# Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

> clinical trial · VERIFIED · 2026-07-01

Status: ACTIVE_NOT_RECRUITING · Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Condition: ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

- Company: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05987956

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.